Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 1;127(13):2279–2293. doi: 10.1002/cncr.33449

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

The phase 1 clinical trial design for nelfinavir (NFV) with chemoradiation in cervical cancer is illustrated. (A) Patients were enrolled at the time they were diagnosed with stage IB to IVA cervical cancer. Patients received 1 week of NFV pretreatment before the initiation of 7 to 9 weeks of standard‐of‐care chemoradiation with cisplatin and combined external‐beam radiotherapy (EBRT) and brachytherapy (XRT). Patients were evaluated for toxicity throughout treatment and at each follow‐up visit for 1 year. Imaging was performed at baseline and at 3, 6, and 12 months after treatment. Tumor biopsies were obtained (A) at baseline, (B) after 1 week of NFV pretreatment, (C1) at 4 weeks or (C2) 6 weeks after the initiation of chemoradiation, and (D) 3 months after treatment. Gy/fx indicates grays per fraction.